Weird, but 2013 revenue (blue bar) and earnings (gray bar) expectations are lower than 2012. Biotech companies will be begin to report first-quarter earnings soon but Meacham and Kasimov expect strong results across the board, which means analysts and investors will be raising their 2013 forecasts. The "Beat and Raise" routine is usually good for stock prices.
Biotech Multiples Are Soaring But M&A Is Dead
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts